Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beam Therapeutics Inc. - Common Stock
(NQ:
BEAM
)
19.88
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
June 28, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies
June 27, 2025
Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.
Via
Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
June 20, 2025
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Via
Investor's Business Daily
Topics
Government
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
June 18, 2025
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Via
Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
June 17, 2025
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.
Via
Investor's Business Daily
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
June 13, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab
June 11, 2025
Via
Benzinga
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
June 03, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 29, 2025
From
Beam Therapeutics
Via
GlobeNewswire
BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025
May 23, 2025
Via
Investor Brand Network
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
May 14, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
May 13, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 12, 2025
From
Beam Therapeutics
Via
GlobeNewswire
10 Analysts Assess Beam Therapeutics: What You Need To Know
May 07, 2025
Via
Benzinga
Why Beam Therapeutics Stock Tanked on Tuesday
May 06, 2025
Via
The Motley Fool
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 06, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
April 21, 2025
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Via
Investor's Business Daily
Topics
Government
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
April 21, 2025
Via
Benzinga
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease
April 07, 2025
Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND
Via
Benzinga
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
April 05, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
April 04, 2025
Via
Benzinga
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed'
April 04, 2025
Via
Benzinga
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
March 28, 2025
Via
Benzinga
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock
March 28, 2025
Via
Benzinga
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
March 27, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
March 22, 2025
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.
Via
Benzinga
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
March 10, 2025
Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.
Via
Benzinga
Beam Therapeutics Announces Pricing of Underwritten Offering
March 10, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
March 10, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%
March 04, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.